<DOC>
	<DOCNO>NCT01346397</DOCNO>
	<brief_summary>After alemtuzumab induction , follow kidney transplantation , patient randomly assign receive either tacrolimus cyclosporine microemulsion combination mycophenolates . Patients follow include protocol biopsy 1 , 12 , 36 , 60 month posttransplant , regular nuclein acid test ( NAT ) cytomegalovirus ( CMV ) , Epstein-Barr virus ( EBV ) BK virus ( BKV ) urine blood . The investigation undertaken clarify reason equal survival rate patient cyclosporine tacrolimus despite low rejection rate tacrolimus .</brief_summary>
	<brief_title>Study Cyclosporine ( CsA ) Versus Tacrolimus ( Tacro ) After Campath Induction Kidney Transplantation</brief_title>
	<detailed_description>Special attention pay epidemiology virus infection behind one year post transplant . Very limited data available issue suspicion tacrolimus patient suffer hard virus like CMV , EBV , BKV . These virus induce graft nephropathy threat life recipient .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>first kidney allograft recipient alemtuzumab induction CNI intolerance</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>rejection</keyword>
	<keyword>survival</keyword>
	<keyword>alemtuzumab</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>tacrolimus</keyword>
</DOC>